Collagenous colitis is a type of inflammatory bowel disease that causes chronic, watery, non-bloody diarrhea. It gets its name from an abnormally thick band of collagen that forms beneath the surface lining of the colon, visible only under a microscope. Because the colon looks completely normal during a standard colonoscopy, a tissue biopsy is the only way to confirm the diagnosis. It falls under the broader category of “microscopic colitis,” alongside a related condition called lymphocytic colitis.
Symptoms and What They Feel Like
The hallmark symptom is persistent watery diarrhea that lasts more than four weeks. Most people experience 4 to 9 watery bowel movements per day, though severe cases can involve 15 or more. The diarrhea is always non-bloody, which helps distinguish it from conditions like ulcerative colitis or Crohn’s disease.
About half of patients also have abdominal pain, cramping, or bloating. Fecal urgency is common, meaning you feel a sudden, hard-to-ignore need to find a bathroom. Some people experience fecal incontinence, especially at night. Nausea, weight loss, and dehydration can develop over time if the diarrhea goes untreated. Because collagenous colitis is a form of inflammatory bowel disease, it occasionally causes symptoms outside the gut, including joint pain, joint inflammation, or eye inflammation.
Who Gets It
Collagenous colitis predominantly affects older adults and is significantly more common in women than men. The typical patient is a woman over 60, though it can occur at any age, including rarely in children and teenagers. The condition is also linked to other autoimmune diseases, particularly celiac disease, thyroid disorders, and rheumatic conditions. If you already have one autoimmune diagnosis, your risk is higher.
Causes and Risk Factors
The exact cause is unknown, but the leading theory involves an abnormal immune response in the colon lining. Despite the name, the thickened collagen band itself probably isn’t what causes the diarrhea. Research using detailed measurements of collagen thickness found that stool volume correlates with the degree of inflammation in the tissue, not with how thick the collagen layer is. The collagen buildup appears to be a byproduct of the inflammatory process rather than the driver of symptoms.
Several common medications are associated with an increased risk. A systematic review and meta-analysis found that proton pump inhibitors (drugs like omeprazole used for acid reflux) roughly doubled the odds of developing microscopic colitis. SSRIs (a common class of antidepressants) doubled the risk as well, while NSAIDs like ibuprofen and statins (cholesterol-lowering drugs) each carried a moderately elevated risk. For collagenous colitis specifically, NSAIDs showed the strongest and most consistent association. If you develop chronic watery diarrhea while taking any of these medications, it’s worth raising the possibility with your doctor.
How It’s Diagnosed
Collagenous colitis cannot be diagnosed by symptoms alone, blood tests, or imaging. During a colonoscopy, the colon typically looks entirely normal, which is why the condition went unrecognized for decades. Diagnosis requires taking small tissue samples (biopsies) from the colon and examining them under a microscope.
What the pathologist looks for is a thickened band of collagen directly beneath the surface cells of the colon lining. This is what separates collagenous colitis from lymphocytic colitis, the other form of microscopic colitis. In lymphocytic colitis, the collagen layer is normal, but there’s an unusually high number of immune cells (lymphocytes) embedded in the surface lining instead. Both conditions cause the same symptoms and look the same on colonoscopy, so the microscope is the only way to tell them apart.
Treatment Options
The most effective treatment is budesonide, an oral steroid that acts locally in the gut with fewer body-wide side effects than traditional steroids. At a standard starting dose, budesonide induces remission in 77% to 100% of patients. In one large trial, 84.5% of patients achieved remission during an 8-week induction course. The improvement is often dramatic, with diarrhea resolving within days to weeks.
The challenge is relapse. Collagenous colitis frequently returns when treatment stops. In a 12-month maintenance trial, 61% of patients who continued on a low dose of budesonide stayed in remission, compared to just 17% of those switched to a placebo. Many people need long-term low-dose treatment to keep symptoms under control.
For people who prefer to avoid steroids or have mild symptoms, other options exist. Bismuth subsalicylate (the active ingredient in Pepto-Bismol) showed promise in a small trial, with all four treated patients seeing their diarrhea resolve over 8 weeks compared to none on placebo. The evidence base is thin, but it’s a reasonable option to try. Bile acid sequestrants like cholestyramine, sometimes combined with other anti-inflammatory drugs, have also shown benefit. Stopping any implicated medication, particularly PPIs or NSAIDs, can sometimes resolve symptoms on its own.
Long-Term Outlook
Collagenous colitis is a chronic condition, but it’s manageable and does not shorten life expectancy. Some people experience a single episode that resolves and never returns. Others have a relapsing course that requires ongoing treatment. The condition does not damage the colon in ways that lead to surgery, and it does not progress into more severe forms of inflammatory bowel disease.
One reassuring finding is that collagenous colitis is actually associated with a decreased risk of colon cancer. A large observational study found the risk was significantly lower than in the general population, with a standardized incidence ratio of just 0.23. The reasons for this protective effect aren’t understood, but it means that unlike ulcerative colitis or Crohn’s disease, collagenous colitis does not require heightened colon cancer surveillance. Interestingly, the same study did find an elevated rate of a specific type of skin cancer (cutaneous squamous cell carcinoma) in collagenous colitis patients, at roughly three times the expected rate. Whether this reflects shared risk factors or a direct connection isn’t yet clear.